Categories AlphaGraphs, Earnings, Health Care
Infographic: Highlights of Gilead Sciences (GILD) Q3 earnings report
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) Wednesday said its third-quarter earnings increased, aided by higher revenues. The results also exceeded the market’s prediction.
Adjusted earnings increased 29% to $2.11 per share from $1.64 per share a year earlier. Analysts were looking for a smaller bottom-line number.
Net income, on an unadjusted basis, came in at $360 million or $0.29 per share, compared to a loss of $1.17 billion or $0.92 per share in the prior-year period.
Read management/analysts’ comments on Gilead Sciences Q3 earnings
Revenues moved up 17% year-over-year to $6.58 billion in the September-quarter and exceeded the market’s prediction. The company’s stock closed Wednesday’s regular trading lower, hut gained during the after-hours session.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Earnings Preview: Accenture (ACN) likely had a strong start to fiscal 2025
For Accenture plc. (NYSE: ACN), 2024 was a fruitful year marked by positive financial performance. The professional service firm effectively navigated a challenging market environment leveraging its agile business model
Signet Jewelers (SIG): Fashion remains a strong point for the jewelery retailer
Shares of Signet Jewelers Limited (NYSE: SIG) were down over 3% on Tuesday. The stock has dropped 12% over the past three months. The company faced challenges in the third
Pfizer (PFE) reaffirms FY24 forecast; provides FY25 guidance
Pharmaceutical company Pfizer Inc. (NYSE: PFE) Tuesday reaffirmed its financial outlook for fiscal 2024 and provided guidance for fiscal 2025. The company said it achieved the goal of $4 bln
